Dentsply confirms $1.8bn Astra Tech buy; deal propels firm to No 3 in dental implants
This article was originally published in Clinica
Executive Summary
AstraZeneca is to sell its Astra Tech medical device subsidiary to Dentsply International for around $1.8bn in cash, both parties confirmed today. The deal is expected to "more than double" Dentsply's current position in the dental implants market, the York, Pennsylvania firm says, and will enable it to diversify into other medical device markets.